Atrantil, a natural health product for IBS -Digestive issues is now available in Canada
DALLAS, Dec. 11, 2018 /CNW/ -- KBS Research, announced today that Atrantil will now be available for purchase in Canada. Atrantil was issued Natural Product Number (NPN) 80083205 with the claim that it "helps to relieve symptoms of Irritable Bowel Syndrome with constipation (IBS-C) such as bloating and constipation" earlier this year.
"We are so excited to finally bring Atrantil to consumers in Canada," said Dr. Brown, MD, creator and Chief Medical Officer. "We've had strong demand from Canadian citizens over the last three years that suffer from Irritable Bowel Syndrome (IBS) wanting to get Atrantil. It's great we can now make Atrantil available to so many people across Canada that are looking to find relief from their IBS and bloating issues." With the approval of Health Canada, Atrantil has been deemed safe and effective when used in accordance with the product label recommendations.
Since Atrantil's launch in 2015, the product has experienced rapid distribution growth, and now will be available across Canada. Atrantil's unique patented method of action has been the catalyst for the high demand and explosive growth across the globe.
In 2012, KBS Research launched Atrantil, which was developed to treat digestive problems such as bloating, Irritable Bowel Syndrome, and promoting overall digestive health through the use of natural & powerful polyphenols. Atrantil is clinically proven to address Irritable Bowel Syndrome, bloating, abdominal discomfort and changes in bowel habits such as diarrhea and/or constipation. Atrantil is produced using a patented formula comprised of botanical extracts, gluten free and non-GMO ingredients in a capsule format and is available without a prescription. Atrantil is a globally distributed natural product which currently holds patents in fifteen countries. To learn more, please visit www.Atrantil.com/canada.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any diseases.
For further information: Eric Rieger, 214-984-3724, KBS Research, LLC, [email protected]